Free tool
FAERS Monitor: Firmagon
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022201 or its brand name (Firmagon, Degarelix Acetate). Reports on generic versions are filed under their own applications.
Reports
5,333
Serious
3,533
66% of reports
Hospitalization
1,733
Death reported
659
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue412
- injection site pain367
- hot flush329
- injection site erythema293
- death227
- asthenia224
- injection site swelling212
- product storage error209
- disease progression174
- pyrexia171
- prostatic specific antigen increased166
- fall162
- dizziness154
- pain147
- nausea146
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 2 |
| 2009 | 34 |
| 2010 | 79 |
| 2011 | 112 |
| 2012 | 104 |
| 2013 | 140 |
| 2014 | 243 |
| 2015 | 194 |
| 2016 | 332 |
| 2017 | 353 |
| 2018 | 367 |
| 2019 | 350 |
| 2020 | 297 |
| 2021 | 406 |
| 2022 | 479 |
| 2023 | 449 |
| 2024 | 489 |
| 2025 | 571 |
| 2026 | 332 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,826 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| prostatic specific antigen increasedSignal | 166 | 48.1 | 41.4 | 7,520 |
| hot flushSignal | 329 | 17.3 | 15.6 | 5,028 |
| injection site swellingSignal | 212 | 10.9 | 9.6 | 1,906 |
| product storage errorSignal | 209 | 9.4 | 8.3 | 1,571 |
| injection site erythemaSignal | 293 | 9.3 | 8.4 | 2,180 |
| disease progressionSignal | 174 | 5.8 | 5.0 | 690 |
| injection site painSignal | 367 | 4.7 | 4.3 | 1,088 |
| astheniaSignal | 224 | 2.4 | 2.1 | 175 |
| fatigueSignal | 412 | 2.1 | 1.9 | 241 |
| pyrexia | 171 | 1.9 | 1.7 | 79 |
| fall | 162 | 1.9 | 1.6 | 72 |
| dizziness | 154 | 1.2 | 1.0 | 6 |
| death | 227 | 1.0 | 0.9 | 0 |
| pain | 147 | 0.9 | 0.8 | 0 |
| nausea | 146 | 0.7 | 0.6 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.